• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Stockpiled avian influenza A(H7N9) vaccines induce robust, non-neutralizing functional antibodies against antigenically drifted 5th wave A(H7N9) virus

tetano

Editor, Senior Moderator
J Infect Dis. 2019 Jun 5. pii: jiz295. doi: 10.1093/infdis/jiz295. [Epub ahead of print]
[h=1]Stockpiled avian influenza A(H7N9) vaccines induce robust, non-neutralizing functional antibodies against antigenically drifted 5th wave A(H7N9) viruses.[/h] Zhong W[SUP]1[/SUP], Levine MZ[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Human infections caused by avian influenza A(H7N9) viruses have raised concerns of a pandemic. The capability of the current stockpiled A(H7N9) vaccines to induce cross-protective, non-neutralizing functional antibodies against antigenically drifted A(H7N9) viruses has not been evaluated before. Here we show that vaccination with either MF59- or AS03-adjuvanted inactivated A(H7N9) vaccines elicited robust, cross-reactive ADCC-mediating and neuraminidase-inhibiting functional antibodies against the antigenically drifted A(H7N9) viruses that emerged recently during the 5th wave outbreak in China, including a highly pathogenic A(H7N9) human isolate. Such cross-reactive humoral immunity may provide vital first-line defense against fatal outcomes in case of a A(H7N9) pandemic.
Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.


[h=4]KEYWORDS:[/h] ADCC; antibody; hemagglutinin; influenza A virus; neuraminidase; vaccines

PMID: 31169293 DOI: 10.1093/infdis/jiz295
 
Back
Top Bottom